VTP 43742

Drug Profile

VTP 43742

Alternative Names: VTP43742

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Allergan
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • Phase I Autoimmune disorders
  • Preclinical Multiple sclerosis

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 14 Sep 2016 Allergan enters into a definitive merger agreement with Vitae Pharmaceuticals
  • 16 Mar 2016 Positive top-line efficacy, pharmacodynamics and adverse events data from a phase IIa trial in Psoriasis released by Vitae Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top